| Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer GR Oxnard, KS Thress, RS Alden, R Lawrance, CP Paweletz, M Cantarini, ... Journal of clinical oncology 34 (28), 3375-3382, 2016 | 898 | 2016 |
| Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer AG Sacher, C Paweletz, SE Dahlberg, RS Alden, A O’Connell, N Feeney, ... JAMA oncology 2 (8), 1014-1022, 2016 | 611 | 2016 |
| Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients CP Paweletz, AG Sacher, CK Raymond, RS Alden, A O'Connell, SL Mach, ... Clinical Cancer Research 22 (4), 915-922, 2016 | 310 | 2016 |
| Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer M Bahcall, T Sim, CP Paweletz, JD Patel, RS Alden, Y Kuang, AG Sacher, ... Cancer discovery 6 (12), 1334-1341, 2016 | 152 | 2016 |
| Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium BT Li, F Janku, B Jung, C Hou, K Madwani, R Alden, P Razavi, ... Annals of Oncology 30 (4), 597-603, 2019 | 143 | 2019 |
| Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients Y Hu, RS Alden, JI Odegaard, SR Fairclough, R Chen, J Heng, N Feeney, ... Clinical Cancer Research 23 (23), 7351-7359, 2017 | 76 | 2017 |
| Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas JM Sands, T Nguyen, P Shivdasani, AG Sacher, ML Cheng, RS Alden, ... Lung Cancer 140, 35-41, 2020 | 32 | 2020 |
| Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers. AJ Redig, ES Chambers, CA Lydon, SE Dahlberg, RS Alden, PA Janne Journal of Clinical Oncology 34 (15_suppl), 9087-9087, 2016 | 23 | 2016 |
| 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC GR Oxnard, KS Thress, RS Alden, R Lawrance, CP Paweletz, M Cantarini, ... Journal of Thoracic Oncology 11 (4), S154, 2016 | 18 | 2016 |
| Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials RS Alden, SJ Mandrekar, GR Oxnard Chinese clinical oncology 4 (3), 37-37, 2015 | 17 | 2015 |
| Prospective validation of rapid plasma genotyping as a sensitive and specific tool for guiding lung cancer care AG Sacher, C Paweletz, SE Dahlberg, RS Alden, A O’Connell, N Feeney, ... JAMA oncology 2 (8), 1014, 2016 | 15 | 2016 |
| Early intervention in lung cancers with rapid plasma genotyping for EGFR and KRAS mutations—reply AG Sacher, RS Alden, GR Oxnard JAMA oncology 2 (8), 1096-1097, 2016 | 11 | 2016 |
| Glutamine metabolism and radiosensitivity: Beyond the Warburg effect RS Alden, MZ Kamran, BA Bashjawish, BA Simone Frontiers in Oncology 12, 1070514, 2022 | 7 | 2022 |
| Outcomes following stereotactic body radiotherapy with intensity-modulated therapy versus three-dimensional conformal radiotherapy in early stage non-small cell lung cancer M Mix, S Tanny, T Nsouli, R Alden, R Chaudhari, R Kincaid, ... Lung Cancer: Targets and Therapy, 151-159, 2019 | 7 | 2019 |
| Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium BT Li, F Janku, PA Janne, GB Mills, K Madwani, RS Alden, CP Paweletz, ... Cancer Research 76 (14_Supplement), 4342-4342, 2016 | 6 | 2016 |
| Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR Y Kuang, A O’Connell, AG Sacher, N Feeney, RS Alden, GR Oxnard, ... Digital PCR: Methods and Protocols, 193-207, 2018 | 5 | 2018 |
| A prospective study of rapid plasma genotyping utilizing sequential ddPCR and NGS in newly diagnosed advanced NSCLC patients AG Sacher, C Paweletz, R Alden, A O'Connell, L Lim, C Raymond, ... JOURNAL OF THORACIC ONCOLOGY 10 (9), S248-S248, 2015 | 3 | 2015 |
| EP07. 02-09 Hypofractionated Radiation Therapy vs Stereotactic Body Radiation Therapy for Ultra-Central Lung Tumors R Song, C Burrows, T Nsouli, R Alden, J Bogart, M Mix Journal of Thoracic Oncology 18 (11), S527-S528, 2023 | | 2023 |
| MA18. 04 Prognostic Factors in Limited-Stage Small Cell Lung Cancer (LSCLC): Secondary Analysis of CALGB 30610 (Alliance)/RTOG 0538 MK Farris, M Mix, X Wang, BL Jaszewsk, N Foster, G Masters, F Laurie, ... Journal of Thoracic Oncology 18 (11), S166-S167, 2023 | | 2023 |
| P1. 17-24 Treatment of Ultracentral Lung Tumors with Hypofractionated Radiation Therapy T Nsouli, R Alden, W Ennis, M Mix, J Bogart Journal of Thoracic Oncology 14 (10), S617, 2019 | | 2019 |
